Sofiva Genomics Co (6615) Fair Value & Analysis
Healthcare · TW · Market cap 754M TWD
Fair value as of: Jul 23, 2026
From 13 valuation models · updated 18 days ago
Share price −7.2% over the past month.
Below-average quality, and screening another 74% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (10.12 TWD). The favourable scenario is already priced in.
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 29.20 TWD – 81.68 TWD · fair‑value band 7.75 TWD – 10.12 TWD · the 34.00 TWD price screens above the 8.94 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 23, 2026.
Analysis
Sofiva Genomics Co (6615) currently trades at 34.00 TWD, while our model-based Fair Value estimate is 8.94 TWD, implying the stock looks roughly 73.7% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Sofiva Genomics Co generated revenue of 383M TWD at a net margin of 2.2%. Revenue declined 3.0% year over year. It earns a return on equity of 1.4%. Fundamentals as of Jul 23, 2026
Our scenario range runs from 7.75 TWD (bear case) to 10.12 TWD (bull case); at 34.00 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 18% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -74%, 6615 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Asset-Based (19.49 TWD) versus Dividend Discount (2.51 TWD). Highest evidence: Growth DCF (72).
Notify me when 6615 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 57
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally.
Full company description
Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M); and prenatal testing services, such as non-invasive prenatal screening, array, karyotyping, maternal serum screening for down syndrome, risk assessment for early/late-onset preeclampsia, folate metabolism genetic testing, congenital infection screening,carrier scan, thalassemia genetic testing, spinal muscular atrophy genetic testing, and fragile X syndrome genetic testing. It also provides baby genetic testing comprising sensorineural hearing loss genetic testing; congenital central hypoventilation syndrome genetic testing (CCHS); and congenital cytomegalovirus infection testing (CMV). In addition, the company offers cancer screening services, which includes human papillomavirus screening (HPV); and hereditary cancer testing services. Further, it develops precision medicine genetic testing; and offers testing services to patients and carriers with rare disorders. Sofiva Genomics Co.,Ltd. was founded in 2012 and is based in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sofiva Genomics Co reported revenue of 386M TWD in FY2025 versus 508M TWD in FY2021, a compound −6.7%/yr. Reported net income was −9.4M TWD in FY2025.
6615 screens 74% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Sofiva Genomics Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sofiva Genomics Co (6615) overvalued or undervalued?
What is the fair value of 6615?
What is the quality score of 6615?
What is the revenue of Sofiva Genomics Co (6615)?
What is the net profit margin of 6615?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sofiva Genomics Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.